Infinity Pharmaceuticals sees FY12 revenue $47.1M, consensus $113.91M Infinity expects FY12 total revenue $47.1M composed of $45.0M for reimbursed R&D services from Mundipharma and $2.1M due to the amortization of deferred revenue. Infinity does not expect to recognize any revenue in future periods from the previous strategic alliance with Purdue and Mundipharma. Infinity expects FY12 operating expenses $125M-$135M revised from an earlier expectation of $135M-$145M. Infinity expects FY12 net loss $35M-$45M. Cash and investments: Infinity expects to end 2012 with a year-end cash and investments balance ranging from $155M-$165M, revised from an earlier expectation of $65M-$75M.
News For INFI From The Last 14 Days
Check below for free stories on INFI the last two weeks.
On The Fly: Analyst Initiation Summary Today's noteworthy initiations include: Chicago Bridge & Iron (CBI) initiated with a Buy at Deutsche Bank... Fluor (FLR) initiated with a Buy at Deutsche Bank... Infinity Pharmaceuticals (INFI) initiated with an Outperform at Wells Fargo... Jacobs Engineering (JEC) initiated with a Hold at Deutsche Bank... KBR (KBR) initiated with a Buy at Deutsche Bank... MasTec (MTZ) initiated with a Buy at Deutsche Bank... McDermott (MDR) initiated with a Hold at Deutsche Bank... Merit Medical (MMSI) initiated with a Hold at Benchmark Co... Ocean Power (OPTT) initiated with a Strong Buy at Ascendiant Capital... Quanta Services (PWR) initiated with a Buy at Deutsche Bank... ZELTIQ Aesthetics (ZLTQ) initiated with a Buy at Maxim... Evercore Partners (EVR) initiated with a Positive at Susquehanna... Alexander & Baldwin (ALEX) initiated with an Outperform at JMP Securities... Myriad Genetics (MYGN) coverage resumed with an Overweight at Stephens... Pinnacle Foods (PF) initiated with a Buy at Janney Capital.